ChromaDex Corp. (CDXC) Completes Enrollment of First Human Clinical Trial for Proprietary pTeroPure Product
ChromaDex Corp., an innovative natural products and proprietary science-based solutions and ingredients for the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, has completed the enrollment of the first human clinical study of its proprietary pTeroPure. The company will evaluate the efficacy and safety of pTeroPure’s in lowering cholesterol and blood pressure, as well as improve markers for oxidative stress in patients with dyslipidemia. "Now that trial enrollment is successfully completed, we anticipate release of the trial data in Q2 2012. This first human clinical study of pTeroPure will provide an important independent clinical assessment of what we believe…